MyBioSource

protein

Recombinant Integrin Beta 3 (ITGb3)

MBS2011765

0.01 mg

225 USD

MBS2011765

Recombinant Protein

Recombinant Integrin Beta 3 (ITGb3)

Integrin Beta 3 (ITGb3)

integrin beta-3; Integrin beta-3; integrin beta-3; platelet membrane glycoprotein IIIa; integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61); Platelet membrane glycoprotein IIIa

ITGb3

ITGB3; ITGB3; GT; CD61; GP3A; BDPLT2; GPIIIa; BDPLT16; GP3A; GPIIIa

ITB3_HUMAN

E Coli

788

The target protein is fused with two N-terminal Tags, His-tag and S-tag, its sequence is listed below. MHHHHHHSSG LVPRGSGMKE TAAAKFERQH MDSPDLGTDD DDKAMADIGS EF- DYPVDI YYLMDLSYSM KDDLWSIQNL GTKLATQMRK LTSNLRIGFG AFVDKPVSPY MYISPPEALE NPCYDMKTTC LPMFGYKHVL TLTDQVTRFN EEVKKQSVSR NRDAPEGGFD AIMQATVCDE KIGWRNDASH LLVFTTDAKT HIALDGRLAG IVQPNDGQCH VGSDNHYSAS TTMDYPSLGL MTEKLSQKNI NLIFAVTENV VNLYQNYSEL IPGTTVGVLS MDSSNVLQLI VDAYGKI

> 95%

Supplied as lyophilized form in PBS, pH7.4, containing 1mM DTT, 5% trehalose, 0.01% sarcosyl and preservative.

Avoid repeated freeze/thaw cycles. Store at 2-8 degree C for one month. Aliquot and store at -80 degree C for 12 months. Stability Test: The thermal stability is described by the loss rate of the targetprotein. The loss rate was determined by accelerated thermal degradation test,that is, incubate the protein at 37 degree C for 48h, and no obvious degradation andprecipitation were observed. (Referring from China Biological Products Standard,which was calculated by the Arrhenius equation.) The loss of this protein is lessthan 5% within the expiration date under appropriate storage condition.

SDS-PAGE, Western Blot (WB), ELISA (EIA), Immunoprecipitation (IP). (May be suitable for use in other assays to be determined by the end user.)

Organism: Homo sapiens (Human). Expression System: Prokaryotic expression. Residues: n/a. Predicted isoelectric point: 5.3

Endotoxin Level: Reconstitute in sterile PBS, pH7.2-pH7.4. Subcellular Location: Membrane; Single-pass type I membrane protein. Usage: Reconstitute in sterile PBS, pH7.2-pH7.4.

About the Marker: Effective Size Range: 10kDa to 70kDa. Protein bands: 10kDa, 14kDa, 18kDa, 22kDa, 26kDa, 33kDa, 44kDa and70kDa. Double intensity bands: The 26kDa, 18kDa, 10kDa bands are at doubleintensity to make location and size approximation of proteins of interestquick and easy. Ready-to-use: No need to heat, dilute or add reducing agents before use.

47078292

NP_000203.2

NM_000212.2

P05106

32.9 kDa

Arf6 Signaling Events Pathway 138034!!Arrhythmogenic Right Ventricular Cardiomyopathy Pathway 672454!!Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Pathway 117293!!Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Pathway 116129!!Axon Guidance Pathway 105688!!Cell Surface Interactions At The Vascular Wall Pathway 106062!!Developmental Biology Pathway 477129!!Dilated Cardiomyopathy Pathway 121494!!Dilated Cardiomyopathy Pathway 121285!!ECM Proteoglycans Pathway 833812

The ITGB3 protein product is the integrin beta chain beta 3. Integrins are integral cell-surface proteins composed of an alpha chain and a beta chain. A given chain may combine with multiple partners resulting in different integrins. Integrin beta 3 is found along with the alpha IIb chain in platelets. Integrins are known to participate in cell adhesion as well as cell-surface mediated signalling. [provided by RefSeq, Jul 2008]

Function: Integrin alpha-V/beta-3 is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. Subunit structure: Heterodimer of an alpha and a beta subunit. Beta-3 associates with either alpha-IIb or alpha-V. Isoform Beta-3C interacts with FLNB. Interacts with COMP. Interacts with HIV-1 Tat. Interacts with PDIA6 following platelet stimulation. Interacts with SYK; upon activation by ITGB3 promotes platelet adhesion. Interacts with MYO10. Interacts with DAB2. Interacts with FERMT2. Alpha-V/beta-3 interacts with herpes virus 8/HHV-8 glycoprotein B and acts as a receptor for the virus. Ref.19 Ref.21 Ref.22 Ref.23 Ref.24 Ref.25 Ref.29 Ref.32. Subcellular location: Cell membrane; Single-pass type I membrane protein. Cell projection lamellipodium membrane. Cell junction focal adhesion Ref.32. Tissue specificity: Isoform beta-3Aand isoform beta-3Care widely expressed. Isoform beta-3Ais specifically expressed in osteoblast cells; isoform beta-3Cis specifically expressed in prostate and testis. Post-translational modification: Phosphorylated on tyrosine residues in response to thrombin-induced platelet aggregation. Probably involved in outside-in signaling. A peptide (AA 740-762) is capable of binding GRB2 only when both Tyr-773 and Tyr-785 are phosphorylated. Phosphorylation of Thr-779 inhibits SHC binding. Ref.18 Ref.20. Polymorphism: Position 59 is associated with platelet-specific alloantigen HPA-1 (ZW or PL(A)). HPA-1A/ZW(A)/PL(A1) has Leu-59 and HPA-1B/ZW(B)/PL(A2) has Pro-59. HPA-1A is involved in fetal-maternal alloimmune thromobocytopenia (FMAIT) as well as in neonatal alloimmune thrombocytopenia (NAIT).Position 169 is associated with platelet-specific alloantigen HPA-4 (PEN or YUK). HPA-4A/PEN(A)/YUK(A) has Arg-169 and HPA-4B/PEN(B)/YUK(B) has Gln-169. HPA-4B is involved in neonatal alloimmune thrombocytopenia (NAIT or NATP).Position 433 is associated with platelet-specific alloantigen MO. MO- has Pro-433 and MO+ has Ala-433. MO+ is involved in NAIT.Position 515 is associated with platelet-specific alloantigen CA/TU. CA-/TU- has Arg-515 and CA+/TU+ has Gln-515. CA+ is involved in NAIT.Position 662 is associated with platelet-specific alloantigen SR(A). SR(A)- has Arg-662 and SR(A)+ has Cys-662. Involvement in disease: Glanzmann thrombasthenia (GT) [MIM:273800]: A common inherited disease of platelet aggregation. It is characterized by mucocutaneous bleeding of mild-to-moderate severity. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb-IIIa complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the GPIIb-IIIa complex at reduced levels, have detectable amounts of fibrinogen, and have low or moderate clot retraction capability.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.41 Ref.42 Ref.43 Ref.44 Ref.45 Ref.46 Ref.47 Ref.48 Ref.49 Ref.50 Ref.53 Ref.55 Ref.56 Ref.57 Ref.58 Ref.59 Ref.60 Ref.62Bleeding disorder, platelet-type 16 (BDPLT16) [MIM:187800]: An autosomal dominant form of congenital macrothrombocytopenia associated with platelet anisocytosis. It is a disorder of platelet production. Affected individuals may have no or only mildly increased bleeding tendency. In vitro studies show mild platelet functional abnormalities.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.61. Sequence similarities: Belongs to the integrin beta chain family.Contains 1 VWFA domain.

0.01 mg

225 USD